Advertisement
Screener

TENAX THERAPEUTICS, INC. (TENX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.0 / 5 stars · 17/43 Roast Me

TENAX THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

TENAX THERAPEUTICS, INC. (TENX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-07-31

  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-03-31 was 0.00%.
  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.00%.
  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
  • TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 8 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-06-300.00%
10-Q · filed 2026-07-31
2026-03-310.00%
10-Q · filed 2026-05-12
2024-09-300.00%
10-Q · filed 2024-11-13
2024-06-300.00%
10-Q · filed 2024-08-13
2024-03-310.00%
10-Q · filed 2024-05-14
2023-12-310.00%
10-K · filed 2024-03-28
2023-09-300.00%
10-Q · filed 2023-11-13
2023-06-300.00%
10-Q · filed 2023-08-14
2023-03-310.00%
10-Q · filed 2023-05-15
2018-09-300.00%
10-Q · filed 2018-11-14
2018-06-300.00%
10-Q · filed 2018-08-14
2017-12-310.00%
10-K · filed 2019-04-01
2017-09-300.00%
10-Q · filed 2018-11-14
2017-06-300.00%
10-Q · filed 2018-08-14
2016-12-310.00%
10-K · filed 2018-04-02
2016-09-300.00%
10-Q · filed 2017-11-09
2016-06-300.00%
10-Q · filed 2017-08-09
2016-03-310.00%
10-Q · filed 2016-05-10
2015-12-310.00%
10-K · filed 2017-03-16
2015-10-310.00%
10-Q · filed 2015-12-10
2015-09-300.00%
10-Q · filed 2016-11-09
2015-07-310.00%
10-Q · filed 2015-09-09
2015-06-300.00%
10-Q · filed 2016-08-09
2015-04-300.00%
10-K · filed 2017-03-16
2015-03-310.00%
10-Q · filed 2016-05-10
2015-01-310.00%
10-Q · filed 2015-03-17
2014-10-310.00%
10-Q · filed 2015-12-10
2014-07-310.00%
10-Q · filed 2015-09-09
2014-04-300.00%
10-K · filed 2017-03-16
2014-01-310.00%
10-Q · filed 2015-03-17
2013-10-310.00%
10-Q · filed 2014-12-15
2013-07-310.00%
10-Q · filed 2014-09-15
2013-04-300.00%
10-KT · filed 2016-03-14
2013-01-310.00%
10-Q · filed 2014-03-17
2012-10-310.00%
10-Q · filed 2013-12-17
2012-07-310.00%
10-Q · filed 2013-09-17
2012-04-300.00%
10-K · filed 2013-06-26
2012-01-310.00%
10-Q · filed 2013-03-18
2011-10-310.00%
10-Q · filed 2012-12-14
2011-07-310.00%
10-Q · filed 2012-09-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Cingulate Inc. (CING)United States$0.073B-2.64
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
XBiotech Inc. (XBIT)United States$0.066B-1.56
OS Therapies Inc (OSTX)United States$0.076B-2.17